Close Menu

NEW YORK (GenomeWeb) — Arcis Biotechnology and Andrew Alliance announced today that they have signed an agreement to comarket their respective technologies for automated nucleic acid stabilization and preparation.

Under the terms of the deal, the partners will promote the use of Arcis' reagents for DNA and RNA preparation with Andrew Alliance platforms, including the Andrew+ pipetting robot, and its OneLab lab protocol design and execution software.

Additional terms were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The former commissioner of the FDA has returned to the venture capital firm New Enterprise Associates as a special partner on the healthcare investment team.

Astronauts have edited yeast genes on the International Space Station in an experiment designed to show how cells repair themselves in space.

Emory University has found that two of its researchers failed to divulge they had received funds from China, according to the Atlanta Journal-Constitution.

In Science this week: influence of the nuclear genome on human mitochondrial DNA, and more.